Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22366703 | 0.77 | TAAR1 (0.38) | TAAR1KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL18185032 | 0.76 | TAAR1 (0.37) | TAAR1KDM4ESMN1; SMN2ALDH1A1ADRA2B | |
| SCHEMBL8370064 | 0.72 | TAAR1 (0.41) | TAAR1KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL18184978 | 0.71 | ADORA2A (0.36) | TAAR1KDM4ESMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL3714554 | 0.71 | KMT2A (0.45) | KDM4ESMN1; SMN2ALDH1A1TDP1TSHR | |
| Ammonia Solution, Strong SCHEMBL3451387 | 0.71 | TAAR1 (0.39) | TAAR1KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3854634 | 0.70 | CD44 (0.39) | TAAR1KCNH2ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL111658 | 0.70 | TAAR1 (0.47) | TAAR1KDM4ESMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL588658 | 0.69 | ALDH1A1 (0.40) | TAAR1KDM4ESMN1; SMN2ALDH1A1ADRA2B | |
| SCHEMBL9729259 | 0.69 | SMN1; SMN2 (0.35) | TAAR1KDM4ESLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| EP-1487822-A2 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | TAAR1 3651/4885KDM4E 739/4885SLC6A2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.